Estimated annual cost of arterial hypertension treatment in Brazil

• Autor(a) principal: Dib, Murilo William [UNIFESP]
• Data de Publicação: 2010
• Outros Autores: Riera, Rachel [UNIFESP], Ferraz, Marcos Bosi [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892010000200006; http://repositorio.unifesp.br/handle/11600/45511
• topic: Hypertension; costs and cost analysis; health economics; Brazil

Objectives. To estimate the direct annual cost of systemic arterial hypertension (SAH) treatment in Brazil's public and private health care systems, assess its economic impact on the total health care budget, and determine its proportion of the 2005 gross domestic product (GDP).Methods. A decision tree model was used to determine direct costs based on estimated use of various resources in SAH diagnosis and care, including treatment (medication and non-medication), complementary exams, doctor visits, nutritional assessments, and emergency room visits.Results. Estimated direct annual cost of SAH treatment was approximately US$ 398.9 million for the public health care system and US$ 272.7 million for the private system, representing 0.08% of the 2005 GDP (ranging from 0.05% to 0.16%). With total health care expenses comprising about 7.6% of Brazil's GDP, this cost represented 1.11% of overall health care costs (0.62% to 2.06%)-1.43% of total expenses for the Unified Healthcare System (Sistema Unico de Sa de, SUS) (0.79% to 2.75%) and 0.83% of expenses for the private health care system (0.47% to 1.48%).Conclusion. To guarantee public or private health care based on the principles of universality and equality, with limited available resources, efforts must be focused on educating the population on prevention and treatment compliance in diseases such as SAH that require significant health resources.